Moleculin Biotech Announces Preclinical Data Showing Annamycin Antitumor Activity In Pancreatic Cancer Is Immune-Mediated
Data presented at the AACR Conference on Pancreatic Cancer indicate Annamycin’s antitumor activity is partially mediated by CD8+ T cells, supporting a potential immune-mediated mechanism alongside its direct cytotoxic
Scientists found that Moleculin's cancer medicine works partly by boosting the body's immune system. When you watch this stock, notice if more test results support this immune angle.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.